Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal status as defined by amenorrhea for \>12 months, OR history of bilateral salpingoophrectomy, OR if the patient has had a hysterectomy defined by menopausal symptoms for \>1 year OR age \>55~2. Documented recurrent UTIs (3 or more in the last year or 2 or more in the last 6 months)- one UTI must be documented by culture, others may be documented by urinalysis~3. Ability to provide informed consent~Exclusion Criteria:~1. Use of any investigational drug or device within thirty days of screening~2. Urologic surgery within the past 3 months of screening or plan for surgery within one year of screening~3. Diagnosis of Interstitial Cystitis/painful bladder syndrome~4. History of urinary tract infections which require the use of IV antibiotics or where only one oral antibiotic is available for treatment, or where the risk of treatment with vaginal estrogen only is deemed unacceptable by the principle investigator secondary to the severity of prior urinary tract infections~5. Known etiology of infection such as, but not limited to: kidney or bladder stones, enterovaginal/vesical fistula, fecal incontinence, intermittent catheterization, indwelling catheter, poorly controlled diabetes~6. Urothelial cancer~7. Actively treated estrogen sensitive tumor (breast or endometrial cancer)~8. Undiagnosed vaginal bleeding~9. Inability to use a vaginal ring (secondary to advanced prolapse or shortened vaginal length)~10. Any medical reason the investigator deems incompatible with treatment with vaginal estrogen~11. Prolapse requiring pessary use~Deferral Criteria~1. Undiagnosed hematuria - may enroll after malignancy is ruled out~2. Use of a progestin containing intrauterine device or use of any vaginal androgens, estrogens or progestins within 3 months of enrollment - may enroll after wash out~3. Use of drugs/supplements known to prevent UTIs (ie cranberry products, prophylactic antibiotics, methenamine hippurate) 1 month prior to enrollment - may enroll after wash out if still meets inclusion criteria.~4. History of estrogen sensitive tumor (breast or endometrial cancer) - requires approval by the subject's primary oncologist or primary care physician

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Conjugated Estrogen Vaginal Cream (Type: EXPERIMENTAL): Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
- Estradiol Ring (Type: EXPERIMENTAL): Estradiol Ring per vagina every 3 months
- Placebo (Type: PLACEBO_COMPARATOR): Per vagina

Based on this trial design, predict the completion outcome and termination type (if applicable).